Rocketvax, Ltd.
RocketVax AG is a Swiss biotech company focused on developing next-generation vaccines based on live-attenuated virus technology. Their mission is to develop vaccines for established and new indications, addressing unmet medical needs in infectious diseases. They are working on promising vaccine candidates RVX-sCPD9 and RVX-OTS to prevent infection with SARS-CoV-2 variants, utilizing proprietary molecular biology technologies. The company is part of the Swiss Rockets group, a biotech incubator in Switzerland, and collaborates with leading Swiss research institutions and international partners. RocketVax aims to create innovative medicines for cancer and viral diseases, with a focus on COVID-19, auto-immune disorders, and cancer. They have a pipeline that includes discovery, preclinical research, clinical trials, and commercial stages. Their technology platform involves rational genetic design for live-attenuated vaccines applicable to various viruses, including coronaviruses, influenza, herpes, and others. The company has received backing from the US government Project NextGen, and has strategic collaborations and investments, including with Emergent BioSolutions and HALIX. RocketVax has achieved significant breakthroughs in live-attenuated SARS-CoV-2 vaccine development, with promising preclinical results, and is progressing towards clinical trials.
Industries
Nr. of Employees
small (1-50)
Rocketvax, Ltd.
Basel, Basel-Stadt, Switzerland, Europe
Products
Live-attenuated intranasal SARS-CoV-2 vaccine candidates (preclinical)
Preclinical-stage intranasal vaccine candidates based on attenuated live-virus constructs designed to induce local mucosal and systemic immunity and reduce transmission.
Live-attenuated intranasal SARS-CoV-2 vaccine candidates (preclinical)
Preclinical-stage intranasal vaccine candidates based on attenuated live-virus constructs designed to induce local mucosal and systemic immunity and reduce transmission.
Services
Clinical manufacturing process development (CDMO partnership)
Development of clinical manufacturing processes and production of clinical trial material through technical collaboration with contract manufacturing partners, including process intensification approaches.
Preclinical study design and execution (transmission and efficacy)
Design and execution of in vivo preclinical studies to evaluate immunogenicity, safety and transmission interruption in respiratory virus models.
Regulatory and clinical trial collaboration support
Coordination with government research institutes and trial sponsors to prepare for and initiate early-phase human clinical trials.
Clinical manufacturing process development (CDMO partnership)
Development of clinical manufacturing processes and production of clinical trial material through technical collaboration with contract manufacturing partners, including process intensification approaches.
Preclinical study design and execution (transmission and efficacy)
Design and execution of in vivo preclinical studies to evaluate immunogenicity, safety and transmission interruption in respiratory virus models.
Regulatory and clinical trial collaboration support
Coordination with government research institutes and trial sponsors to prepare for and initiate early-phase human clinical trials.
Expertise Areas
- Live-attenuated vaccine development
- Mucosal/intranasal vaccine delivery
- Preclinical animal efficacy and transmission studies
- GMP clinical manufacturing process development and scale-up
Key Technologies
- Genome recoding / codon-pair deoptimization
- Live-attenuated vaccine platforms
- Single-cycle replication vaccine design
- Intranasal/nasal vaccine formulation and delivery